Abstract
Introduction Researchers routinely evaluate novel biomarkers for incorporation into clinical risk models. Although of potential benefit, such emerging markers, which are often costly or not yet commercially available, are unlikely to enable the scalable risk assessment needed for population health strategies. In contrast, the ideal inputs for population approaches would be those already widely available for most patients. We hypothesized that simple hematologic markers, available in an outpatient complete blood count without differential, would be useful to develop risk models for cardiovascular events.
Methods Using routine laboratory measurements as predictors and neural network-based automated event adjudication of 1,072,348 discharge summaries, we developed and validated models for prediction of heart attack, ischemic stroke, heart failure hospitalization, revascularization, and all-cause mortality.
Results Models with hematology indices alone showed Harrell’s concordance index ranging from 0.60–0.80 on an external validation set. Hematology indices added significantly in terms of discrimination and calibration performance compared to models using only demographic data and diagnostic codes for coronary artery disease, heart failure, and ischemic stroke, with the concordance index of resulting models in the range 0.75–0.85 on an external validation set. Predictive features varied by outcome, and included red blood cell, leukocyte, and platelet indices.
Conclusion We conclude that low-cost ubiquitous inputs, if biologically informative, can provide population-level readouts of risk.
Competing Interest Statement
R.C.D is supported by grants from the National Institute of Health, the American Heart Association (One Brave Idea, Apple Heart and Movement Study) and GE Healthcare, has received consulting fees from Novartis and Pfizer, and is co-founder of Atman Health. C.A.M. is a consultant for Pfizer and co-founder of Atman Health.r Pfizer and co-founder of Atman Health.
Funding Statement
This work was supported by One Brave Idea, co-founded by the American Heart Association and Verily with significant support from AstraZeneca and pillar support from Quest Diagnostics (to CAM and RCD), SENSHIN Medical Research Foundation (to SG), the Kanae foundation for the promotion of medical science (to SG), the Mower fellowship (to SG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complies with all ethical regulations and guidelines. The study protocol was approved by local institutional review boards (IRB) of Mass General Brigham (2019P002651)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author R.C.D. upon approval of the data sharing committees of the respective institutions. The data are not publicly available due to the presence of information that could compromise research participant privacy.
